A televised offer buys a place in a medical intake queue, not a prescription. On the terms published at ro.co in July 2026, the advertised entry price opens an online visit, a licensed provider decides whether treatment is appropriate, and the membership charge applies only to people found eligible. Medication is a second bill that arrives later.
The advertised figure sits in front of a clinical decision
The most misread feature of any broadcast healthcare offer is the conditional buried inside it. Ro’s pricing page states a first membership month at $39 and adds that the $39 is refunded to anyone not found eligible for a GLP-1. That is a real protection, and it is also a signal about the shape of the transaction. At the moment a viewer responds to an ad, nobody yet knows whether a prescription will be written.
Eligibility here is not a formality. Obesity pharmacotherapy guidance ties candidacy to body mass index thresholds and to weight-related conditions, and a 2025 framework on defining clinical obesity argues for assessment built on organ and tissue dysfunction rather than a weight category by itself. A prescriber reviewing an intake can decline, ask for laboratory work, or route someone toward in-person care. An advertisement has no way to promise the outcome of that review, and a well-written one does not try.
Two days, then two rails that behave nothing alike
Ro’s published timeline gives an eligibility answer within two days. What happens next depends entirely on which payment rail a patient lands on, and the two rails produce different experiences from that point forward.
On the cash rail, the medication ships to a home address and the company describes a first dose in under a week. On the insurance rail, a concierge verifies benefits and files prior authorization paperwork, a process the company puts at roughly one to three weeks, after which a covered prescription goes to a retail pharmacy for collection at the plan copay. Same company, same prescription, two schedules that differ by weeks. Anyone comparing accounts of how fast the process moved is often comparing rails rather than service quality.
Ro is one entry in a crowded field, and the mechanics above repeat with small variations across it. Hims and Hers and Henry Meds run their own membership-plus-medication structures, LillyDirect sells the branded drug through a manufacturer channel, and providers such as HealthRX publish their own intake and pricing for GLP-1 medications. Lining up how each one separates the eligibility step, the access fee, and the pharmacy bill is the only way to tell which advertised figure is describing the same thing.
Refills are dose events, and dose events are billing events
Every approved medication in this class climbs a titration ladder, and the published cash prices climb with it. Ro’s tables show a starting dose priced well below a maintenance dose on each product. That structure matters because the trial results that make these drugs famous were produced at the top of the ladder rather than the bottom. Semaglutide was studied at 2.4 mg weekly in STEP 1, tirzepatide reached 10 mg and 15 mg weekly in SURMOUNT-1, and the oral small molecule orforglipron was tested across a dose range in its obesity program. Those were separate trials in different populations and are not a head-to-head comparison, but each describes sustained treatment at maintenance strength.
So a refill is rarely a repeat of the previous month. It is usually the next rung, and the next rung frequently carries a different price.
| Stage | What has to be true to advance | Which charge attaches | Where it commonly stalls |
|---|---|---|---|
| Online visit | Health history submitted in full | None yet | Missing weight history or prior treatment detail |
| Eligibility decision | A provider finds treatment appropriate | Membership fee, refunded if not eligible | Referral out for in-person assessment |
| Insurance verification | Plan covers a GLP-1 for this use | Copay at a retail pharmacy | Prior authorization, roughly one to three weeks |
| Cash route | Self-pay terms accepted | Medication price for that specific dose | Dose tier is higher than the advertised one |
| First fill | Prescription routed to fulfillment | Nothing additional | Cash ships home, insured scripts are collected in person |
| Dose increase | Provider approves escalation | New dose price | The medication line moves without warning |
| Renewal | Plan term rolls over | Membership again, on its term | Prepaid terms renew as a block, not monthly |
What the support layer is built to handle
Ro describes its membership as covering a treatment plan, one-to-one provider messaging, check-ins, coaching, an insurance concierge, and laboratory testing where a clinician orders it. The same page states plainly that the cost of medication is not included in the membership fee. Read as a product description rather than a sales line, that tells a prospective member exactly where the support boundary sits: the fee buys clinical access and administrative help, and the pharmacy bill is its own event.
It also explains why questions get routed differently. A message about nausea is a clinical question that goes to a provider. A message about an unexpected charge is a billing question that goes somewhere else entirely, and the two queues rarely move at the same speed.
The questions worth settling before the first charge
Three answers make the rest of the process predictable. What is the price of the dose most people end up on, not the dose everyone starts on. Whether an insurance path will be attempted first, and how long that adds. And what the plan term is, since a prepaid term converts a monthly decision into a longer one.
Structure differs by business model, which is why quotes are hard to line up. Cash-pay compounded programs, including physician-supervised providers such as FormBlends, generally quote one blended monthly figure rather than splitting access from drug, which simplifies the arithmetic but changes the product, because compounded preparations are not FDA-approved and the agency has published its concerns about unapproved GLP-1 products marketed for weight loss.
Frequently asked questions
Does responding to the ad mean a prescription is coming?
No. The advertised entry price starts a medical review, and a licensed provider decides whether treatment is appropriate. Ro states the membership fee is charged only to people found eligible and refunds it otherwise. Anyone treating the sign-up as the purchase of a drug has skipped the step that decides everything.
Why do two people report completely different wait times?
Usually because they are on different payment rails. The cash route is described as delivering a first dose in under a week. The insurance route runs through benefit verification and possible prior authorization, which the company puts at one to three weeks before a prescription reaches a pharmacy.
Will the monthly medication cost stay where it started?
Not typically. Published prices are set per dose, and dosing escalates on a schedule set out in approved labeling. The figure that belongs in a budget is the price at maintenance strength, since that is where the studied weight outcomes were produced and where most treatment settles.
What is the difference between the membership and the medication bill?
The membership covers provider access, messaging, check-ins, coaching, insurance help, and clinician-ordered labs. The medication is billed separately, either as a cash price for a specific dose or as a pharmacy copay if a plan covers it. Two charges, two schedules, two reasons they can change.
